Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Pheochromocytoma 1Paraganglioma 1Ovarian Neoplasms 1Kidney Neoplasms 1Gastrointestinal Stromal Tumors 1Fallopian Tube Neoplasms 1Carcinoma, Renal Cell 1

Interventions

aldesleukin 23Bevacizumab 17Magnetic Resonance Spectroscopy 15Specimen Handling 12Sunitinib 11Sorafenib 11Interferon-alpha 11cabozantinib 9Cyclophosphamide 9Nivolumab 8Immunoglobulin G 7Disulfides 7temsirolimus 6fludarabine phosphate 5Sirolimus 5Introns 5Fluorouracil 5Erlotinib Hydrochloride 5Chemotherapy, Adjuvant 5sargramostim 4cediranib 4bryostatin 1 4Vorinostat 4Neoadjuvant Therapy 4Ipilimumab 4Interleukin-2 4Interferon alpha-2 4Biopsy 4vandetanib 3ixabepilone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Carcinoma, Renal Cell × guadecitabine × Clear all
NCT03165721 2026-02-18

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
9 enrolled 11 charts
CNSEndocrineGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Kidney Neoplasms, Paraganglioma, Pheochromocytoma, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡